Paris - Delayed Quote EUR

bioMérieux S.A. (BIM.PA)

Compare
97.65 -0.70 (-0.71%)
As of 12:07 PM GMT+1. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Pierre Boulud Chief Executive Officer 1.35M -- 1971
Mr. Guillaume Bouhours Executive VP of Purchasing and Information Systems & CFO -- -- 1976
Sylvain Morgeau Investor Relations -- -- --
Ms. Audrey Dauvet Executive Vice President of Legal, Corporate Integrity & Public Affairs -- -- 1974
Ms. Valerie Leylde Executive Vice President of Human Resources, Communications & CSR -- -- --
Mr. Pierre Charbonnier Executive Vice President of Global Quality, Manufacturing & Supply Chain -- -- --
Mr. Yasha Mitrotti Executive Vice President of Industrial Applications -- -- --
Mr. Frederic Beseme Head of CSR 21.99k -- 1956
Jennifer Zinn Executive Vice President of Clinical Operations -- -- --
Dr. Charles K. Cooper Executive VP & Chief Medical Officer -- -- --

bioMérieux S.A.

376 Chemin De l’Orme
Marcy-l'étoile, 69280
France
33 4 78 87 20 00 https://www.biomerieux.com
Sector:?
Healthcare
Full Time Employees:?
13,409

Description

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Corporate Governance

bioMérieux S.A.’s ISS Governance QualityScore as of November 1, 2024 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 30, 2024 at 6:15 AM UTC

bioMérieux S.A. Earnings Date

Recent Events

June 7, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers